恩格列净与利尿剂在射血分数保留心衰中的安全性和疗效:EMPEROR-Preserved试验事后分析
该事后分析纳入EMPEROR-Preserved试验中5815例HFpEF患者,按基线利尿剂使用及剂量分组。
要点
- 恩格列净在HFpEF患者中降低HHF或心血管死亡风险不受基线利尿剂使用或剂量影响。
- 恩格列净可减少利尿剂剂量升级并增加降级可能性,可能优化利尿剂管理。
- 使用利尿剂的患者中,恩格列净增加容量不足风险,需监测。
核心结论
- 恩格列净在HFpEF患者中的疗效不受基线利尿剂使用或剂量影响,且可减少传统利尿剂剂量。
研究设计与样本
- EMPEROR-Preserved试验的事后分析,纳入5815例有基线利尿剂数据的HFpEF患者。
- EMPEROR-Preserved为3期随机双盲安慰剂对照试验,2017年3月至2021年4月进行。
主要发现
- 在安慰剂组中,较高利尿剂剂量与更差结局相关。
- 恩格列净与利尿剂剂量升级可能性降低相关(HR 0.74;95%CI 0.65-0.84),与降级可能性增加相关(HR 1.15;95%CI 1.02-1.30)。
- 恩格列净与使用利尿剂患者容量不足风险增加相关(HR 1.34;95%CI 1.13-1.59)。
关键数值与推荐
- 基线利尿剂使用分布:无利尿剂20.3%,<40 mg 29.7%,40 mg 30.5%,>40 mg 19.6%。
- 利尿剂剂量升级HR 0.74(95%CI 0.65-0.84),降级HR 1.15(95%CI 1.02-1.30)。
- 容量不足风险HR 1.34(95%CI 1.13-1.59)。
临床怎么用
- HFpEF患者使用恩格列净时无需因基线利尿剂状态或剂量调整用药。
- 恩格列净可能有助于减少利尿剂剂量,但需监测容量不足风险。
局限性
- 为事后分析,结果需谨慎解读。
- 利尿剂剂量以呋塞米等效剂量表示,可能存在转换误差。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The diuretic effect of sodium-glucose cotransporter 2 inhibitors may result in interaction with background diuretic therapy in patients with heart failure and preserved ejection fraction (HFpEF). OBJECTIVE: To assess the safety and efficacy of empagliflozin in combination with background diuretic therapy and the association of empagliflozin with the need for conventional diuretics. DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc analysis of the Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction (EMPEROR-Preserved). EMPEROR-Preserved was a phase 3, randomized, placebo-controlled, double-blind clinical trial conducted from March 2017 to April 2021. Patients with class II to IV heart failure and left ventricular ejection fraction greater than 40% were included. Of 5988 patients enrolled, 5815 (97.1%) had baseline data on diuretic use and were included in this analysis, which was conducted from November 2021 to August 2022. INTERVENTIONS: Participants in EMPEROR-Preserved were randomized to empagliflozin or placebo. In this analysis, participants were divided into 4 subgroups: no diuretics and furosemide-equivalent diuretic dose of less than 40 mg, 40 mg, and greater than 40 mg at baseline. MAIN OUTCOMES AND MEASURES: The main outcomes of interest were first hospitalization for heart failure (HHF) or cardiovascular death (CV death) and its components. Association of empagliflozin vs placebo with outcomes by baseline diuretic status (no diuretic vs any dose) and dose (no diuretic, <40 mg, 40 mg, and > 40mg) was assessed. Association of empagliflozin use with changes in diuretic therapy was also studied. RESULTS: Among 5815 patients (mean [SD] age, 71.9 [9.4] years; 2594 [44.6%] female) with known baseline diuretic use, 1179 (20.3%) were not taking diuretics, 1725 (29.7%) were taking less than 40 mg, 1772 (30.5%) were taking 40 mg, and 1139 (19.6%) were taking greater than 40 mg. In the placebo arm, patients with higher diuretic doses had worse outcomes. Empagliflozin decreased the risk of HHF or CV death, regardless of background diuretic status (hazard ratio [HR], 0.81; 95% CI, 0.70-0.93] for the diuretic group vs HR, 0.72; 95% CI, 0.48-1.06 for the nondiuretic group; P for interaction = .58). Similarly, diuretic status was not associated with changes in improvements in first HHF, total HHF, rate of decline in estimated glomerular filtration rate, and Kansas City Cardiomyopathy Questionnaire 23 clinical summary score with empagliflozin. Findings were consistent when patients were categorized by diuretic dose. Empagliflozin was associated with a decreased likelihood of diuretic dose escalation (HR, 0.74; 95% CI, 0.65-0.84) and an increased likelihood of de-escalation (HR, 1.15; 95% CI, 1.02-1.30). Empagliflozin was associated with an increased risk of volume depletion in patients taking diuretics (HR, 1.34; 95% CI, 1.13-1.59). CONCLUSION: In this study, treatment with empagliflozin was similar regardless of diuretic use or dose. Empagliflozin use was associated with decreased conventional diuretic dosing. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03057951.
引用
- Butler, Usman, Filippatos, et al. Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved Trial. JAMA Cardiol. 2023. PMID: 37223933. doi:10.1001/jamacardio.2023.1090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。